A retinal camera the size of a coffee maker, an AI quiet enough not to brag, and a thesis: the eye is the cheapest window we have into the rest of the body.
It is a Saturday in a school gymnasium that Remote Area Medical has rented out for the weekend. There is no ophthalmologist on site. There is a medical assistant who finished a 20-minute training video on Tuesday, a laptop, and a portable retinal camera with a soft voice. A diabetic patient in his fifties sits down, rests his forehead against the cushion, and a virtual assistant speaks calmly into the room. Look at the green dot. Hold still. Blink. Good. Sixty seconds later his fundus is in the cloud, an AI has measured his vessels, and a board-certified reader two states away is composing a report.
This is identifeye HEALTH at work in 2026 - not in a research paper, not in a press release, but in the kind of room where most American screening actually has to happen if it is going to happen at all.
The company spent six years engineering toward that scene. The hardest part, it turns out, was making it look unremarkable.
identifeye HEALTH (formerly Tesseract Health) sells a portable fundus imager, a cloud portal, and - eventually - an AI toolkit that reads the images. The retina is the only spot in the body where a clinician can watch blood vessels and nerves directly. Diabetic retinopathy hides there. So do early signs of glaucoma, macular degeneration, and - the bet that pays the rent later - cardiovascular and neurological disease.
FDA 510(k)-exempt fundus imager with an audio virtual assistant that walks patients through the scan. Designed so a clinic with no ophthalmologist can still capture diagnostic-grade images in minutes.
HIPAA-compliant cloud for device management, image review, EHR integration and patient reporting. Customers can read in-house or send images to a board-certified remote reader.
The machine-learning layer for screening and monitoring of retinal biomarkers and systemic disease. Not yet commercially available in the U.S. The interesting question is what happens when it is.
Serial medtech founder behind Butterfly Network, Hyperfine, Quantum-Si and Detect. identifeye is a 4Catalyzer spinout. Rothberg's pattern: take an expensive medical instrument and shrink it until a primary-care clinic can afford one.
Optics and imaging engineer. Quietly responsible for the part of the product that has to actually focus on a retina without dilation and without a trained operator.
UC Berkeley chemical engineer. Twenty years in healthcare products. Before identifeye, she helped develop GRAIL's Galleri multi-cancer early-detection test. Her second act is moving early detection from blood to eyeball.
An integrated audio virtual assistant guides the patient through the scan. It is the kind of UX nobody puts on a marketing slide and everybody needs the moment a nervous diabetic sits down.
The whole point is that the operator can be a medical assistant with minutes of training. That is a software problem disguised as a hardware spec.
The AI toolkit isn't shipping in the U.S. yet. Most medtech startups would lead with the AI; identifeye is leading with the picture and earning its way to the diagnosis.
The Facebook and Instagram handles still say tesseracthealth. The company has chosen to ship product instead of renaming social accounts. Read into that what you like.
If you run a primary-care clinic, a community-health program, or a health system that screens diabetics and rarely sees them again, identifeye is selling you a way to keep screening compliance from collapsing. The patient sits down once, the camera and the cloud do the rest, and the clinician gets a report they can put in front of a person who came in to refill a prescription.
Mobile-clinic screenings in Ohio using identifeye's retinal platform.
Community cardiovascular and disease-screening program in Maryland.
Lead investor and growth partner since the 2021 Series B.
Eyenuk (EyeArt) and Digital Diagnostics (IDx-DR) own the regulatory front of AI retinal screening. Optomed and Topcon sell the hardware. AEYE Health and Verily are working similar AI angles. Zeiss and Canon make the incumbents identifeye has to be cheaper and easier than.
Series B closed April 20, 2021, led by Foresite Capital. No publicly disclosed valuation. The company has stayed quiet between rounds, which in medtech usually means engineering, regulatory submissions, and patience.
The patient from the opening - the diabetic in his fifties - has left with a printed page. Nothing dramatic on it; mild signs, follow-up suggested, an appointment booked. He is not a press release. He is, however, the entire point.
A decade ago, the camera that just photographed his fundus would have lived in an ophthalmology suite costing tens of thousands of dollars to staff. The image would have waited for a specialist. The follow-up would have been a phone call he might not have returned. Today the camera sits next to a coffee urn and a stack of intake forms, the AI quietly tags what to look at first, and the system sends him home with a number on a page.
identifeye HEALTH did not invent the retina. It did not invent the cloud. It put them in the same room as a medical assistant and got out of the way. That, in healthcare, counts as radical.
Inside the design choices that made the camera operable by a medical assistant with minutes of training.
Why the company shed its old name and what the new identity signals about commercial ambitions.
Tracing the CEO's path from multi-cancer detection to the eye as an early-warning system.
How identifeye fits the pattern set by Butterfly Network, Hyperfine and Quantum-Si.
Using identifeye's RAM deployments to examine the screening gap in U.S. primary care.
A look at the machine-learning roadmap waiting on regulatory clearance.
Reconstructing the Series B thesis from public filings, talks and competitor moves.
Cardiologists, neurologists and endocrinologists all eye the fundus - identifeye wants to be their camera.
What screening looks like when the equipment fits on a folding table.
A close read of the voice UX that walks anxious patients through their first retinal scan.